Report: Merck Looks into Possible Buyout of Seagen

Pharmaceutical giant Merck is exploring a possible purchase of biotech company Seagen, according to The Wall Street Journal.

No deal is imminent, sources told the publication, noting the challenge of regulatory approval. If Merck does not go through with the purchase, the companies could reach a marketing deal.